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Impaired sleep and enhanced stress hormone secretion are the hallmarks of stress-related
disorders, including major depression. The central neuropeptide, corticotropin-releasing
hormone (CRH), is a key hormone that regulates humoral and behavioral adaptation to stress.
Its prolonged hypersecretion is believed to play a key role in the development and course of
depressive symptoms, and is associated with sleep impairment. To investigate the specific
effects of central CRH overexpression on sleep, we used conditional mouse mutants that
overexpress CRH in the entire central nervous system (CRH-COE-Nes) or only in the forebrain,
including limbic structures (CRH-COE-Cam). Compared with wild-type or control mice during
baseline, both homozygous CRH-COE-Nes and -Cam mice showed constantly increased rapid
eye movement (REM) sleep, whereas slightly suppressed non-REM sleep was detected only in
CRH-COE-Nes mice during the light period. In response to 6-h sleep deprivation, elevated
levels of REM sleep also became evident in heterozygous CRH-COE-Nes and -Cam mice during
recovery, which was reversed by treatment with a CRH receptor type 1 (CRHR1) antagonist in
heterozygous and homozygous CRH-COE-Nes mice. The peripheral stress hormone levels
were not elevated at baseline, and even after sleep deprivation they were indistinguishable
across genotypes. As the stress axis was not altered, sleep changes, in particular enhanced
REM sleep, occurring in these models are most likely induced by the forebrain CRH through
the activation of CRHR1. CRH hypersecretion in the forebrain seems to drive REM sleep,
supporting the notion that enhanced REM sleep may serve as biomarker for clinical conditions
associated with enhanced CRH secretion.
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Introduction
Corticotropin-releasing hormone (CRH) is a neuro-
peptide involved in the coordination of the humoral
and behavioral response to stress.
1–3 Prominent
features of stress-elicited adaptations include in-
creased anxiety, enhanced tension and arousal, as
well as activation of the hypothalamic–pituitary-
adrenocortical (HPA) axis.
Both the sleep–wake regulatory system and the
HPA axis are intertwined, as administration of CRH,
adrenocorticotropic hormone (ACTH) and corticoster-
oids produce distinct effects upon changes in vigi-
lance states, detected by means of sleep elec-
troencephalogram (EEG) in humans and animals.
4–6
All these studies monitored the sleep EEG after acute
or chronic treatment. For example, in healthy hu-
mans, repeated intravenous (i.v.) injections of CRH
7
and continuous i.v. infusion of ACTH
8 produced
reductions of slow-wave sleep (SWS), correspond-
ingly non-rapid eye movement (non-REM) sleep in
rodents. Likewise, intracerebroventricular (i.c.v.) ad-
ministration of CRH to rats resulted in enhanced
wakefulness and suppression of non-REM sleep.
9,10
I.c.v.-injected ACTH
11 and prolonged systemic infu-
sion of corticosteroids
12 in rats also decreased non-
REM and REM sleep. These results suggest that the
activation of the HPA axis contributes to wake
responses under stress exposure. However, it re-
mained unclear whether all the stress hormones acted
on sleep directly or indirectly together, or separately
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www.nature.com/mpthrough feedback action on CRH. Further, central
administration of high dosages of CRH would give
only an indirect reflection of stress-evoked CRH
secretion.
To circumvent these problems, we used conditional
mouse mutants in which overexpression of different
CRH dosages is restricted to the central nervous
system (CNS) or in a more confined manner to the
anterior forebrain, including limbic structures. These
mice do not show overt behavioral or endocrine
abnormalities, for example, weight loss or hypercorti-
solism, under resting conditions, but respond with
increased active stress-coping behavior and corticos-
terone release under stress conditions.
13 Here, we
could show that the significant contribution of the
brain region-specific CRH to sleep is an enhancement
of REM sleep that is independent from its capacity
of HPA activation. Furthermore, we showed that the
effects of CRH on sleep–wake control are mediated
through the CRH type 1 receptors (CRHR1), as the
administration of a specific CRHR1 antagonist re-
versed elevated REM sleep in mice conditionally
overexpressing CRH (CRH-COE) during recovery after
sleep deprivation (SD). Finally, we propose that the
CRH-COE mouse line would be an ideal animal model
to investigate the effect of spatially confined CRH
hyperactivity and also aid to validate drug candidates
targeting the central CRH system.
Materials and methods
Animals
A detailed description of the generation and char-
acterization of conditional CRH-overexpressing mice
has been described elsewhere.
13 Briefly, CNS-re-
stricted overexpression of CRH (CRH-COE-Nes) was
achieved by breeding of R26
flopCrh/flopCrh (flop, floxed
stop) mice to transgenic nestin (Nes)-Cre mice.
14 For
the forebrain-restricted overexpression of CRH in
principal neurons (CRH-COE-Cam), R26
flopCrh/flopCrh
mice were crossed to transgenic Camk2a-Cre
mice.
15 In the F2 generation, we obtained R26
þ/þ,
R26
flopCrh/flopCrh, R26
þ/flopCrh Nes-/Camk2a-Cre and
R26
flopCrh/flopCrh Nes-/Camk2a-Cre mice, which we will
refer to as CRH-COE
wt-Nes/-Cam, CRH-COE
con-Nes/-
Cam, CRH-COE
het-Nes/-Cam and CRH-COE
hom-Nes/-
Cam, respectively. Genotyping was carried out by PCR
using primers: ROSA-1, 50-AAAGTCGCTCTGAGTT
GTTAT-30; ROSA-5, 50-TAGAGCTGGTTCGTGGTGTG-
30; ROSA-6 50-GCTGCATAAAACCCCAGATG-30 and
ROSA-7, 50-GGGGAACTTCCTGACTAGGG-30. Stan-
dard PCR conditions resulted in a 398-bp wild-type
and a 646-bp mutant PCR products. Animals with a
premature deletion of the floxed transcriptional
terminator sequence were identified by the occur-
rence of a 505-bp PCR product and were excluded
from the studies. The presence of Nes- or Camk2a-Cre
was evaluated using primers CRE-F, 50-GATCGCTGC
CAGGATATACG-30, CRE-R 50-AATCGCCATCTTC
CAGCAG-30, CTSQ-up 50-ACAAGGTCTGTGAATCAT
GC-30 and CTSQ-dn 50-TTACAATGTGGATTTTG
TGGG-30, resulting in a Cre-specific PCR product
of 574bp and a control PCR product of 1098bp. CRH-
COE-Nes mice were kept on a mixed 129S2/
Sv C57BL/6J SJL, and CRH-COE-Cam mice on a
mixed 129S2/Sv C57BL/6J CBA/J background, at
the breeding facility of the Max Planck Institute
of Psychiatry. Male littermates, weighing 24–30g
(10–14-week-old) were used for the experiments.
Around the occasion for surgery, animals were
housed individually in a sound-attenuated recording
chamber maintained at a regulated ambient tempera-
ture of 22±11C on a 12-h light/dark cycle (lights on at
0900 hours). The animals had access to water and
food ad libitum. All animal studies were conducted
according to the guidance of the European Commu-
nity Council Directive, and experimental protocols
were approved by the local commission for the Care
and Use of Laboratory Animals of the State Govern-
ment of Bavaria, Germany.
Surgery
The mice were anaesthetized with an intraperitoneal
injection of a ketamine–xylazine mixture (115mg and
11.5mgkg
–1, respectively) and chronically implanted
with EEG and electromyographic (EMG) electrodes for
polysomnographic recordings. The implant consisted
of four stainless steel screws (0.8mm diameter) for
EEG recordings that were placed through the skull
epidur (coordinates, A 1.5mm and 3mm; L±1.7mm
each) and two gold wires inserted into the cervical
portion of the trapezoid muscles for EMG recordings.
All electrodes were soldered to a micro-socket affixed
to the skull with dental acrylic resin. After surgery,
the mice were allowed to spend ca. 10 days for
recovery without cabling in the environment as
mentioned above.
Sleep recordings and data processing
The lead wires of the EEG and EMG electrodes were
connected to an electric swivel through a flexible
tether. The weights of the swivel and tether were
outbalanced through a mechanical device near to
zero; thus the mice could move unrestrictedly and
were acclimated for 3–4 days before the initiation of
recording. EEG and EMG signals were amplified
(10000 ), filtered (EEG 0.5–29Hz, 48dB per Oct.;
EMG underwent root mean square rectification), and
digitized by a high-speed analog-to-digital converter
at a sampling rate of 64Hz. Then the signals were
processed by a PC equipped with a LabVIEW
program, especially designed for sleep EEG analysis
(National Instruments, SEA Ko ¨ln, Germany). Poly-
graphic data were all stored on a computer and
processed offline later with the LabVIEW-based
acquisition program, in which a Fast Fourier Trans-
form (FFT) algorithm served for power spectrum
analysis of particular EEG frequency contents,
that is, d (0.5–5Hz), y (6–9Hz), a (10–15Hz) and b
(16–29Hz). Using the aid of the FFT algorithm,
adapted from a report by Louis et al.,
16 the spectral
analysis was also undertaken to serve semiautomatic
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awake, non-REM sleep or REM sleep that were
defined in 4-s epochs. Defined vigilance states were
further confirmed visually and corrected if necessary.
Summed power densities of slow-wave activity
(SWA) during non-REM sleep were calculated be-
tween 0.5 and 4Hz at a 0.5-Hz bin and normalized by
total EEG power. Epochs containing artifacts were
eliminated from power spectral analysis.
Baseline recordings were initiated nearly 2 weeks
after the animals had received surgical operation, and
24-h spontaneous sleep–wake patterns during base-
line were compared among the different genotypes.
Then, 6-h SD was applied from the beginning of the
onset of the light period (at 0900 hours, that is,
Zeitgeber time 0, ZT0) by gentle handling. During the
SD period, examiners paid careful attention to the
mice by playing with cotton swabs or tissue papers
and so on, not to touch their body directly. Meantime,
polygraphical recordings were continuously made,
and we were able to cut off 97.5% of non-REM sleep
and 100% of REM sleep on an average. Over the SD
paradigm, differences in recovery sleep were evalu-
ated among the genotypes.
CRHR1 antagonist
DMP696, generously provided by Bristol-Myers
Squibb, was administered orally 1h before the end
of the SD session as a suspension in 0.25% methyl-
cellulose at the dose of 30mgkg
–1. The dose and the
timing of administration were chosen according to an
earlier report, in which DMP696 blocks stress-
induced ACTH secretion.
17 The same animals re-
ceived vehicle only (0.25% methylcellulose in sterile
water) as a control group on the other day at the same
timing during SD. Drug volumes were 5mlkg
–1.
Analyses of plasma corticosterone
Baseline blood was withdrawn from the tail vein (ca.
20ml) 5–6 days before performing SD with the same
timing either equivalent to the end of 6-h SD (ZT6) or
6h after SD (ZT12). On the day of SD, the same
animals were killed at ZT6 or ZT12, and trunk blood
was collected for further hormonal analyses. After
collection, these blood samples were immediately
separated into plasma and red blood cells by
centrifugation for 15min at 4000c.p.m. at 41C. Plasma
levels of corticosterone were measured using a radio-
immunoassay (RIA) kit (MP Biomedicals, Orangeburg,
NY, USA). The sensitivity of the corticosterone RIA
kit is 25ngml
–1. The intra-assay and inter-assay
coefficients of variation were <12% for corticoster-
one.
In situ hybridization
The brain-specific overexpression of CRH in CRH-
COE-Nes and CRH-COE-Cam mice was verified by
quantitative in situ hybridization. Detailed proce-
dures concerning in situ hybridization are provided
in Supplementary Materials and Methods.
Statistical analysis
Time spent awake in non-REM and REM sleep was
calculated in 1, 2, 12 or 24h averages. Differences in
sleep–wake patterns during baseline and recovery
after SD were compared among different genotypes
and statistically analyzed using either nonparametric
two-way analysis of variance (ANOVA) (for 1 or 2h
averages) or one-way ANOVA (for 12 or 24h aver-
ages). The effects of the CRHR1 antagonist on
recovery sleep were evaluated in comparison between
vehicle- and DMP696-treated days. The effects of SD
on the levels of corticosterone were compared with
the basal levels on a day without SD using nonpara-
metric one-way ANOVA. If the F values reached
statistical significance, the Student–Newman–Keuls
multiple comparison test was further applied for post
hoc analysis. A level of P<0.05 was considered
significant.
Results
CNS-specific overexpression of CRH
Nes-Cre- and Camk2a-Cre-mediated excision of the
transcriptional terminator resulted in overexpression
of CRH from the R26 promotor and co-activation of
the LacZ reporter gene (Supplementary Figure 1). The
CNS- and forebrain-restricted overexpression of CRH
in CRH-COE-Nes and CRH-COE-Cam mice, respec-
tively, was confirmed by in situ hybridization and
X-Gal staining (Supplementary Figures 1B–H). As
described earlier,
13 only endogenous CRH expression
was detected in the CNS of CRH-COE
wt-Nes/-Cam and
CRH-COE
con-Nes/-Cam mice (Supplementary Figures
1B, C; data not shown). In CRH-COE
het- and CRH-
COE
hom-Nes mice, expression of exogenous CRH, as
well as of LacZ, was detected throughout the brain
and spinal cord, reflecting the CNS-restricted expres-
sion of Nes-Cre and the ubiquitous activity of the R26
locus (Supplementary Figures 1F–H). In CRH-COE
het-
and CRH-COE
hom-Cam mice, expression of exogenous
CRH was detected in the principal neurons of the
limbic system, reflecting the predominantly fore-
brain-specific expression of Camk2a-Cre (Supple-
mentary Figures 1D, E). Consistently higher CRH
mRNA levels were detected in the brain sections of
CRH-COE
hom-Nes/-Cam mice (Supplementary Figures
1E, G) compared with CRH-COE
het-Nes/-Cam animals
(Supplementary Figures 1D, F), reflecting the gene
dosage effect because of expression of exogenous CRH
from a single or both R26 alleles.
Sleep alteration in CNS-restricted CRH-COE-Nes mice
Spontaneous sleep–wake patterns were monitored,
and the baseline changes in their circadian dynamics
were compared in CRH-COE
wt, con, het, hom-Nes litter-
mates. All genotypes presented circadian-based var-
iation for each vigilance state, showing a typical
nocturnal sleep–wake behavior (Figure 1). CRH-
COE
con-Nes mice showed identical time-course
changes in waking, non-REM sleep and REM sleep
with those seen in CRH-COE
wt-Nes mice (Figure 1,
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het-Nes and CRH-COE
hom-
Nes mice the amount and distribution of sleep and
wakefulness differed from wild-type and control
CRH-COE-Nes mice (Figure 1, Table 1). CRH-COE
het-
Nes mice had elevated wakefulness during the light
period (17.1% more than CRH-COE
con-Nes mice,
P<0.05), whereas non-REM sleep was diminished
in return (10.3% less than CRH-COE
con-Nes mice,
P<0.05) (Figure 1, right and Table 1). Although an
increase in waking time during the light period was
not statistically evident (7.9% more than CRH-
COE
con-Nes mice, P>0.05), CRH-COE
hom-Nes showed
significantly reduced non-REM sleep around the
same period as CRH-COE
het-Nes animals (8.8% less
than CRH-COE
con-Nes mice, P<0.05). On the contrary,
REM sleep was markedly enhanced during light
and dark periods regarding bihourly distribution
(Figure 1, right), whereas the cumulative amount of
REM sleep in either the light period or total 24-h
recording time did not reach the significance level
(19.8 and 29.4% more than CRH-COE
con-Nes mice,
respectively, P>0.05, Table 1). While the level of
REM sleep was upregulated in the dark period
(52.4% more than CRH-COE
con-Nes mice, P<0.05),
the amount of wakefulness was attenuated (5.4% less
than CRH-COE
con-Nes mice, P<0.05, Figure 1, right).
Although CRH-COE
het-Nes mice did not show any
significant increases in REM sleep, the amount of
REM sleep occupying total sleep time tended to be
higher than in wild-type and control CRH-COE-Nes
mice (Table 1). Across the four genotypes such REM
sleep ratio was highest in CRH-COE
hom-Nes mice
(P<0.05), in which disparities in the ratios between
the light and dark period found in control mice
disappeared.
SD triggers more REM sleep during recovery in
CRH-COE-Nes mice
Six-h SD made a significant effect on the disparity of
sleep phenotypes in CRH-COE-Nes mice that had
already been seen during baseline recording. The
comparison of sleep patterns after SD showed that
CRH-COE
hom-Nes mice spent less time in non-REM
sleep than CRH-COE
con-Nes animals (9.5% less than
control during ZT6–12, P<0.05, Figure 2). Although
CRH-COE
het-Nes mice showed a lower amount of
spontaneous non-REM sleep as mentioned earlier,
the rebound of non-REM sleep after SD was similar to
that seen in CRH-COE
con-Nes mice. In contrast, REM
sleep changes were dynamic; CRH-COE
het-Nes and
Figure 1 Time-course changes in sleep–wake patterns of corticotropin-releasing hormone (CRH)-COE-Nes mice. Data points
±s.e.m. indicate 2h averages in time spent in waking, non-rapid eye movement (non-REM) sleep (nonREMS) and REM sleep
(REMS) during a baseline recording day: open circles, CRH-COE
wt-Nes (wt), n=24; hatched area, CRH-COE
con-Nes (Nes con),
n=20; gray circles with dotted line, CRH-COE
het-Nes (Nes het), n=20; black circles with solid line, CRH-COE
hom-Nes (Nes
hom), n=21. Horizontal open bar, light period; horizontal filled bar, dark period. Two-way analysis of variance (ANOVA)
among four genotypes; for waking during the light period F(3, 246)=3.13, P<0.05, during the dark period F(3, 246)=3.01,
P<0.05; for non-REM sleep during the light period F(3, 246)=5.14, P<0.01, during the dark period F(3, 246)=1.71, n.s., for
REM sleep during the light period F(3, 246)=4.32, P<0.01, during the dark period F(3, 246)=9.27, P<0.001. No statistical
significances were found in vigilance between wild-type and control mice (left panels). Heterozygous and homozygous mice
showed significant differences in between or compared with con mice, indicated by its respective line and * (right panels).
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hom-Nes mice displayed highly elevated
REM sleep in response to SD (44.9% (het) and
39.4% (hom) more than controls during ZT6–12,
P<0.05, Figure 2). During the dark period, REM sleep
in CRH-COE
hom-Nes mice remained elevated, but
increased REM sleep compared with other genotypes
had been observed already during baseline recording.
Therefore, changes in nocturnal sleep time were not
really affected by SD, and the rebound in recovery
sleep triggered by SD was mostly detected during
post-SD hours 6–12 (ZT6–12). Although the distribu-
tion of that rebound sleep differed in a genotype-
dependent manner, the peak appearance of rebound
sleep was the same in both cases in non-REM
sleep (between ZT8–10) and REM sleep (between
ZT10–12).
The forebrain-restricted CRH-COE-Cam mice also show
enhanced REM sleep
Spontaneous sleep–wake patterns between wild-type
and control CRH-COE-Nes mice were indistinguish-
able. Therefore, wild-type mice were omitted when
monitoring sleep EEGs from COE-Cam mice. As
shown in Figure 3, CRH-COE
con, het, hom-Cam mice
also showed nocturnal sleep–wake activities. During
the baseline recording, time-course changes in non-
REM sleep were not significantly different from all
three genotypes in both light and dark periods (Figure
3). In contrast, elevated appearance of REM sleep was
demonstrated over the bihourly distribution in CRH-
COE
hom-Cam mice. Significant differences in REM
sleep amounts were found between CRH-COE
hom-Cam
and CRH-COE
con,het-Cam mice during the light period,
and CRH-COE
con -Cam mice during the dark
period (Figure 3). However, the increased level of
REM sleep failed to mark significance when calcu-
lated into either 12-h (21.6% more during the light
period and 46.5% more during the dark period than
CRH-COE
con-Cam mice, P>0.05) or 24-h (28.3% more
than CRH-COE
con-Cam mice, P>0.05) cumulative
summary (Table 1). REM sleep ratios versus total
sleep tended to show higher values in CRH-
COE
het,hom-Cam mice than CRH-COE
con-Cam mice,
but the differences were not as large as in CRH-
COE-Nes mice (Table 1).
After baseline recording, all CRH-COE-Cam mice
were subjected to 6-h SD in succession (Figure 3), and
their recovery sleep was compared across each
genotype. Unlike in CRH-COE-Nes mice, non-REM
sleep responses after SD in CRH-COE-Cam mice were
similar in all genotypes. The peak appearance of non-
REM sleep was observed between ZT6–8, which
occurred earlier in CRH-COE-Cam mice than in
CRH-COE-Nes mice in response to SD. On the
contrary, elevated REM sleep after SD appeared in
both CRH-COE
het,hom-Cam mice similar to CRH-
COE
het,hom-Nes mice. Significantly increased levels
of REM sleep were shown throughout the post-SD
hours 6–24 (ZT6–24), in which CRH-COE
het,hom -Cam
mice spent 26.0 and 33.9%, respectively, more than
CRH-COE
con-Cam mice during the entire SD day
(Figure 3). As elevated REM sleep in CRH-COE
hom-
Cam mice was already observed on the baseline day,
the level of REM sleep after SD in CRH-COE
hom-Cam
mice was not particularly enhanced by SD. However,
in the case of in CRH-COE
het-Cam mice, SD triggered
Table 1 Sleep time during the baseline recording
Genotype nonREMS (min) REMS (min) REMS ratio (%)
N 12-h light 12-h dark 24h 12-h light 12-h dark 24h 12-h light 12-h dark
CRH-COE
wt-Nes 24 414.1±6.3 197.6±10.4 611.7±12.3 91.7±4.8 35.9±3.9 127.5±7.6 18.1±0.9 14.6±1.0
CRH-COE
con-Nes 20 415.6±10.3 194.7±12.4 610.3±19.0 86.3±7.2 35.5±4.5 121.7±10.5 17.1±1.4 15.1±1.5
CRH-COE
het-Nes 20 372.9±13.3** 178.0±14.5 552.8±21.9 89.7±5.8 40.0±5.6 129.8±10.4 19.5±1.1 17.1±1.4
CRH-COE
hom-Nes 21 379.2±9.0** 205.6±10.5 584.2±15.0 103.4±5.9 54.1±5.6*** 157.5±10.2 21.5±1.2* 20.6±1.6**
One-way ANOVA
P-value 0.002 0.439 0.058 0.209 0.028 0.050 0.047 0.010
CRH-COE
con-Cam 9 430.0±13.7 188.7±21.3 618.4±26.6 69.4±7.9 25.0±5.8 94.4±10.0 13.9±1.5 10.9±1.5
CRH-COE
het-Cam 10 404.1±10.0 221.6±25.3 625.7±28.7 72.6±6.9 32.9±5.2 105.5±9.0 15.2±1.4 12.8±1.3
CRH-COE
hom-Cam 11 397.4±9.2 228.6±17.6 626.0±16.0 84.5±6.0 36.6±5.5 121.1±8.5 17.5±1.1 13.2±1.1
One-way ANOVA
P-value 0.109 0.402 0.970 0.269 0.345 0.133 0.165 0.430
Abbreviations: CRH, corticotropin-releasing hormone; nonREMS, non-rapid eye movement sleep; REMS, rapid eye
movement sleep.
Values are means±s.e.m. REMS ratio was calculated as per cent REM sleep in total sleep.
Statistical significances are indicated with asterisks relative to average of CRH-COE
con-Nes only (*), both CRH-COE
wt-Nes and
CRH-COE
con-Nes (**), or all the other genotypes (***), analyzed using one-way analysis of variance (ANOVA) with the
Student–Newman–Keuls multiple comparison test (P<0.05). In the genotype of CRH-COE
con-Cam, no statistical differences
in summarized baseline data were found by one-way ANOVA.
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reached the peak level at ZT8–10 in CRH-COE
het-Cam
mice, but CRH-COE
con,hom-Cam mice showed most
elevated REM sleep between ZT10–11.
The HPA axis is intact in both CRH-COE-Nes and
CRH-COE-Cam mice
In a naive group of animals, plasma levels of
corticosterone were compared before and after SD
to determine whether sleep time loss affects HPA
activity. On the day of SD, the trunk blood was taken
immediately after the end of SD (ZT6) and 6h later
(ZT12). Beforehand, the baseline blood was collected
at ZT6 and ZT12. No differences in basal levels of
plasma corticosterone were found across all geno-
types at neither ZT6 nor ZT12 in both CRH-COE-Nes
and CRH-COE-Cam mice, as we reported earlier
(Figure 4, upper panels).
13 As it is known that the
corticosterone levels naturally increase toward the
dark period, the levels of plasma corticosterone at
ZT12 were higher than those at ZT6 in all genotypes
of CRH-COE-Nes and CRH-COE-Cam mice, although
CRH-COE
het,hom-Cam mice did not show statistical
difference. On the day of SD, plasma levels of
corticosterone at ZT6 and ZT12 did not differ among
genotypes as baseline. However, increases in the
plasma corticosterone levels after SD at ZT6 were
significantly greater in control mice than in the other
mice that had elevated the brain CRH concentrations,
that is, CRH-COE
wt-Nes (3.7 times more, P<0.01) and
CRH-COE
con-Nes mice (3.4 times more, P<0.01)
versus CRH-COE
het-Nes (2.8 times more, P<0.05)
and CRH-COE
hom-Nes mice (2.0 times more,
P<0.05, Figure 4, left); CRH-COE
con-Cam mice (3.2
times more, P<0.01) versus CRH-COE
het-Cam
(1.6 times more, P>0.05) and CRH-COE
hom-Cam mice
(1.5 times more, P>0.05, Figure 4, right).
Antagonizing CRHR1 normalizes enhanced REM sleep
after SD in CRH-COE-Nes mice
To examine whether overproduced CRH signaling
through CRHR1 is responsible for sleep alterations,
especially increases in REM sleep occurring after SD,
we tested a CRHR1 antagonist, DMP696, during SD
and subsequently compared sleep patterns of
DMP696- and vehicle-treated animals. In CRH-
COE
wt-Nes mice, DMP696 did not exert any effects
on recovery sleep. However, in CRH-COE
con-Nes
mice, DMP696 treatment affected the hourly distribu-
tion of REM sleep, but not of non-REM sleep
(Figure 5), showing a slight REM sleep attenuating
effect of the antagonist (Table 2). Such normalizing
effects on sleep were seen more clearly in hetero-
zygous and homozygous CRH-COE-Nes mice.
DMP696 dramatically reduced SD-elicited REM sleep
enhancement in CRH-COE
het-Nes and CRH-COE
hom-
Nes mice. The level of hourly non-REM sleep
remained significantly elevated in both CRH-COE
het-
Nes and CRH-COE
hom-Nes mice under DMP696
(Figure 5). After DMP696 treatment, differences in
REM sleep ratios among the four genotypes were
smaller than after vehicle treatment, indicating that
antagonizing CRHR1 normalized an imbalance
of REM sleep occurrence in CRH-COE-Nes mice
(Table 2).
CRH overexpression affects slow-wave activity
The amplitude or power of SWA expresses the depth
of non-REM sleep, indicating a reflection of accumu-
lated sleep demand as explained in the two-process
model.
18 It is well documented that increased power
spectra of SWA are detected during non-REM sleep
after prolonged wakefulness such as SD.
19 In all
CRH-COE-Nes mice, the magnitude of SWA was
higher at the beginning than at the end of the light
Figure 2 Changes in sleep patterns after sleep deprivation
in corticotropin-releasing hormone (CRH)-COE-Nes mice.
Data points ±s.e.m. indicate 2h averages in time spent in
non-rapid eye movement (non-REM) sleep (nonREMS) and
REM sleep (REMS). Sleep deprivation (SD) was performed
for 6h from the beginning of the onset of the light period
(Zeitgeber time 0, ZT0), indicated by a gray bar. Hatched
area, CRH-COE
con-Nes (Nes con), n=14; gray circles with
dotted line, CRH-COE
het-Nes (Nes het), n=12; black circles
with solid line, CRH-COE
hom-Nes (Nes hom), n=14. Hor-
izontal open bar, light period; horizontal filled bar, dark
period. Two-way analysis of variance among three geno-
types; for non-REM sleep during post-SD hours 6–12 (ZT6–
12) in the light period F(2, 111)=4.13, P<0.05, for REM
sleep during ZT6–12 in the light period F(2, 111)=9.55,
P<0.001, during the 12-h dark period F(2, 222)=4.16,
P<0.05. No statistical significances were found in recovery
sleep between wild-type and control mice (data not shown).
Heterozygous and/or homozygous mice showed significant
differences compared with con mice, indicated by its
respective line and *.
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Molecular Psychiatryperiod during baseline and reached the highest value
after termination of SD (Supplementary Figure 2).
However, CRH-COE
het-Nes mice at baseline showed a
relatively blunted distribution of SWA and its levels
were lowest when compared with those of the other
genotypes (Supplementary Figure 2, P<0.01),
whereas effects of SD on elevated levels of SWA were
not distinguishable across all the three genotypes.
During the dark period, CRH-COE
het, hom-Nes mice
showed lower power spectrum compared with CRH-
COE
con-Nes mice, but the following night after SD, the
power between the three genotypes was not signifi-
cantly different (Supplementary Figure 2). With the
treatment of DMP696, elevated SWA after SD was not
significantly affected in all genotypes, and changes in
the levels of SWA power stayed similar as seen on the
day without treatment (data not shown).
Discussion
Conditional transgenic mouse lines overexpressing
CRH in the brain and specific areas of the brain
allowed us to unravel the role of CRH in sleep–wake
regulation. Earlier attempts were hampered by inter-
ference of the peripheral stress hormones that also
affect sleep. For example, central administration of
CRH to rats, which elicits increased plasma ACTH
and corticosterone concentrations, affects sleep
directly or even through interactions with immuno-
modulators.
9,10,20 Also, conventional CRH-overexpres-
sing mice hypersecrete corticosterone
21 and develop a
Cushing-like phenotype,
22 thus limiting their useful-
ness for studies of sleep physiology. Finally, CRH
receptor antagonists often failed to provide
further insight into the role of CRH in sleep,
10,23–25
as CRH is secreted in pathophysiologically relevant
amounts only if homeostasis is disturbed, rendering
CRH receptor antagonists under resting conditions
ineffective.
Many complex mental diseases, including depres-
sion and anxiety disorders, can be initiated by
inadequate adaptation to stress.
26 Specifically, pro-
longed central secretion of CRH is believed to account
for a number of signs and symptoms characterizing
these disorders.
27,28 Among these symptoms are
manifold sleep disturbances, and polysomnographic
recordings showed disinhibited REM sleep and a
decrease of SWS.
29,30 According to our transgenic
mouse model, CRH accounts for these changes in
sleep architecture. Both CRH-COE
hom-Nes and -Cam
Figure 3 Sleep distributions in corticotropin-releasing hormone (CRH)-COE-Cam mice during baseline and after sleep
deprivation. Data points±s.e.m. indicate 2h averages in time spent in non-rapid eye movement (non-REM) sleep (nonREMS)
and REM sleep (REMS). Sleep deprivation (SD) was performed for 6h from the onset of the light period (Zeitgeber time 0,
ZT0), indicated by a gray bar, following the baseline recording. Hatched area, CRH-COE
con-Cam (Cam con), n=9; gray squares
with dotted line, CRH-COE
het-Cam (Cam het), n=10; black squares with solid line, CRH-COE
hom-Cam (Cam hom), n=11.
Horizontal open bar, light period; horizontal filled bar, dark period. Two-way analysis of variance among three genotypes; on
baseline day for REM sleep during the light period F(2, 162)=4.47, P<0.05, during the dark period F(2, 162)=3.34, P<0.05;
on SD day for REM sleep during ZT6–12 in the light period F(2, 81)=7.94, P<0.001, during the 12-h dark period F(2,
162)=3.33, P<0.05. No statistical significances were found in respect to non-REM sleep on both days across all genotypes.
Heterozygous and/or homozygous mice showed significant differences compared with con mice, indicated by its respective
line and *.
CRH enhances REM sleep
M Kimura et al
160
Molecular PsychiatryFigure 4 Effects of sleep deprivation (SD) on plasma levels of corticosterone in corticotropin-releasing hormone (CRH)-
COE-Nes and CRH-COE-Cam mice. Height±s.e.m. of columns indicates quantities of plasma corticosterone in the blood
samples taken at Zeitgeber time (ZT)6 and 12 separately on baseline day and the day of SD from the same animals. White,
CRH-COE
wt-Nes (wt); light gray, CRH-COE
con-Nes or CRH-COE
con-Cam (con); dark gray, CRH-COE
het-Nes or CRH-COE
het-Cam
(het); black, CRH-COE
hom-Nes or CRH-COE
hom-Cam (hom). Varied numbers of samples in parentheses were due to technical
reasons. * indicates statistical differences in the values during baseline between ZT6 and ZT12, compared with each
respective genotype (P<0.05). * denotes the statistical significance in elevated levels of plasma corticosterone after SD,
compared with the respective baseline (*P<0.05, **P<0.01).
Figure 5 Effects of a corticotropin-releasing hormone receptor type 1 (CRHR1) antagonist, DMP696, on recovery sleep after
sleep deprivation (SD) in CRH-COE-Nes mice. Data points ±s.e.m. indicate 1h averages in time spent in non-rapid eye
movement (non-REM) sleep (nonREMS) and REM sleep (REMS) during 7h after 6-h SD initiated at Zeitgeber time (ZT)0.
Animals received either vehicle or DMP696 per os at ZT5, at 1h before the end of SD. Open and filled symbols indicate sleep
changes after vehicle and antagonist treatment, respectively. Shaded area indicates the dark period. Numbers in brackets
represent the sample size. Two-way analysis of variance for treatment effect between each genotype; CRH-COE
con-Nes for
REM sleep F(1, 132)=4.55, P<0.05; CRH-COE
het-Nes for non-REM sleep F(1, 120)=5.68, P<0.05, for REM sleep F(1,
120)=8.19, P<0.01; CRH-COE
hom-Nes for non-REM sleep F(1, 132)=5.90, P<0.05, for REM sleep F(1, 132)=8.62, P<0.01.
* denotes statistical significance in treatment (P<0.05).
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Heterozygous animals of both mouse lines, which
have only moderately increased brain CRH levels in
respective brain regions, showed similarly elevated
REM sleep in response to forced awakening during
recovery after SD.
As reported by Lu et al.,
13 our conditional CRH
overexpressing mice, that is, heterozygous and homo-
zygous CRH-COE-Nes mice in which the entire brain
is exposed to an overexpression of CRH, show
unaffected plasma ACTH and corticosterone concen-
trations in the morning as well as in the evening.
Accordingly, we failed to observe significant differ-
ences in those stress hormone levels between differ-
ent genotypes at baseline and even after SD, although
restrained stress elicits the stress hormone release in
the CRH-COE
het,hom-Nes mice compared with those in
control littermates.
13 CRH-COE mice do not seem to
recognize sleep loss as a stressor, and undisturbed
HPA axis activity in CRH-COE-Nes and -Cam mice
implies that overexpressed CRH acts only centrally,
not provoking systemic endocrine activity reflected
by plasma ACTH and corticosterone concentrations.
Thus, this genetic mouse model is a suitable tool to
understand the mechanism and function of CRH
within the brain.
The sleep phenotype of enhanced REM sleep is also
present when CRH overexpression is restricted more
specifically within the forebrain. In the CRH-COE-
Cam mice, CRH is overexpressed only in the limited
brain areas including limbic structures, such as the
amygdala, implicated in emotional responses.
31 It is
well known that emotions and REM sleep are closely
related. There is a major projection of CRH pathways
from the amygdala to pontine areas,
32,33 where REM-
on cells are dominant in the cholinergic system.
34
CRH is capable of activating these areas to induce
muscle atonia that is one of the characteristics
accompanying REM sleep.
35 When the amygdala
receives either electric stimulation or cholinergic
activation, prolonged REM sleep occurs.
36,37 Further,
CRH infusion into the central nucleus of the amygdala
(CeA) induces c-Fos expression in the pontine
cholinergic neurons.
38 Accumulated evidence would
support that a mechanism of enhanced REM sleep in
CRH-COE-Cam mice underlies amygdaloid CRH and
pontine cholinergic interaction. As the amygdaloid
circuit plays an important role in the regulation of
REM sleep,
39–41 stress-induced CRH release from the
limbic system plausibly contributes to REM sleep
alteration through this.
42
Unexpectedly, CRH-COE mice did not show a
stereotype of insomnia. Through clinical observation
and data from animal experiments, we suspected that
elevated levels of CRH in the brain would have
suppressed non-REM sleep or increased waking
time.
6,9,10 In contrast, after SD the orally given CRHR1
antagonist increased non-REM sleep in both hetero-
zygous and homozygous CRH-COE-Nes mice, which
implies that under stressful conditions, such as SD,
the brain CRH is also involved in non-REM sleep
disturbances through CRHR1.
43 There is no remark-
able effect of the CRHR1 antagonist in control
animals, in which central CRH excess is limited,
and thus rendering receptor blockade of no avail.
From these observations, we conclude that the
CRHR1 antagonist treatment could be of use to restore
impaired sleep patterns only if CRH stimulation
occurs in a pathophysiological range, such as severe
acute or chronic stress, rather than under normal
circumstances.
44 In this study, the CRHR1 antagonist
affected REM but not non-REM sleep response to SD
in CRH-COE
con-Nes mice. Apparently, REM sleep is
a fragile state and receives a more dominant influ-
ence than non-REM sleep when CRH is excessively
produced in particular parts of the brain.
23,45 The
results from the CRHR1 antagonist treatment in this
model underscore potential effects of central CRH on
sleep through CRHR1, as CRH induces REM sleep and
attenuates non-REM sleep.
20
Table 2 Effects of CRH receptor type 1 antagonist on recovery sleep after 6-h sleep deprivation
Difference Ant.–Veh. (%) REMS ratio (%)
Genotype N nonREMS REMS Veh Ant
CRH-COE
wt-Nes 11 102.9±3.0 103.6±9.3 11.2±1.0 11.3±0.9
CRH-COE
con-Nes 12 104.9±2.0 85.2±6.2 11.7±0.9 9.7±0.7
CRH-COE
het-Nes 11 109.0±3.9 80.2±8.2* 13.3±0.4 10.3±1.0*
CRH-COE
hom-Nes 12 107.8±2.4* 82.2±4.2* 13.5±0.8 10.6±0.6*
One-way ANOVA
P-value 1.000 0.101 0.134 0.601
Abbreviations: Ant., antagonist DMP696; CRH, corticotropin-releasing hormone; nonREMS, non-rapid eye movement sleep;
REMS, rapid eye movement sleep; Veh., vehicle.
Values are means±s.e.m. for 6h during the light period after 6-h sleep deprivation.
Differences were relative values in percentile of sleep amount on a day of antagonist treatment compared with average on
another day of vehicle treatment set as 100%. REMS ratio was calculated as per cent REM sleep in 6-h total recovery sleep.
*Statistical differences from average of corresponding vehicle groups, analyzed by paired t-test (P<0.05). One-way analysis
of variance shows no statistical significance among genotypes.
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animal model that allows to study central hypersecre-
tion of CRH, which is hypothesized to be a key factor
in causality of depression.
28 The genetic engineering
strategy used here allows stable and chronic over-
expression of CRH in the brain,
13 which makes us
capable of experimentally mimicking some aspects
observed in the clinical situation.
46–48 In this model,
the HPA axis is undisturbed under basal conditions,
which does not apply to the cases of stress models
accomplished from selectively bred or genetically
vulnerable strains.
49 Also patients who are recovered
from depression but still carry vulnerability to further
disease episodes have near normal HPA axis activity
though symptom-free.
26 On the other hand, central
CRH hypersecretion is not necessarily reflected by the
peripheral stress hormone excess, as clinical response
to CRHR1 antagonists in depression is not straight-
forwardly predicted by the peripheral stress hormone
assessments.
50 Even in the absence of elevated
HPA activity, however, it is noteworthy that CRH-
COE
hom-Nes and -Cam mice display increased spon-
taneous REM sleep as most other animal models of
depression do.
51–55 It has been always difficult to
dissociate the effects of each separate HPA hormone
on sleep and to offer a mechanism how depression or
stress promotes REM sleep. Exogenous administra-
tion of an unphysiologically high CRH dose triggers
hyperarousal, leaving it unclear by which mechanism
REM sleep is suppressed.
43,56 So far, there are only
few studies that have reported facets of CRH-mediat-
ing REM sleep promotion.
20,57,58 However, certain
stressors, such as immobilization, that is, an inescap-
able situation, are often reported to elicit REM
sleep,
59–61 which suggests an involvement of the
CRH system in REM sleep regulation.
23 These data
yield a supposition that an acute HPA activation
stimulates awakening, but its chronic activation or
protracted recovery process from the acute hyperac-
tivity produces a sleep phenotype resembling that
seen in depressed patients. Our results suggest that a
chronic site-specific overexpression of CRH induces
REM sleep enhancement. This interpretation is not
contradictory to that of Pawlyk et al.
62 who micro-
injected CRH into the CeA of rats and observed a
decrease in REM sleep. Notably not all the brain areas
where our mouse mutants overexpress CRH are
necessarily evoking the same effects on REM sleep.
Also, CRH expression is differentially regulated in
different regions of the limbic system. The herein
demonstrated enhancement of REM sleep could be
viewed as an endophenotype of elevated CRH in the
forebrain, including limbic structures, which may
correspond to REM sleep alteration in depressed
patients
63,64 or increased REM density as a clinical
biomarker among individuals at high risk for affective
disorders.
65
This study is the first report showing that the brain-
derived CRH enhances REM sleep through the
activation of CRHR1. This finding may indicate that
CRHR1 antagonists are suited to restore impaired
sleep and stress-related sleep disorders. Moreover,
our site-specific CRH-COE mouse model suggests that
CRH originating from the forebrain also contributes to
REM sleep increase in patients with major depres-
sion. We emphasize that altered appearance of REM
sleep is likely to be a premorbid sign of hypersecreted
central CRH and may serve as biomarker predicting
an upcoming clinical condition, which can be
prevented by CRHR1 antagonists.
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